Literature DB >> 3090248

Enhanced interleukin 1 and depressed interleukin 2 production in juvenile arthritis.

A Martini, A Ravelli, L D Notarangelo, R Maccario, A Lanfranchi, D Rondena, A G Ugazio, R Burgio.   

Abstract

Blood mononuclear cells from a total of 23 children with juvenile arthritis were stimulated in vitro to produce interleukin 1 (IL-1) and interleukin 2 (IL-2) and compared with age matched healthy controls. Peripheral blood monocytes from patients with juvenile arthritis produced a higher amount of IL-1 than controls, whereas peripheral blood lymphocytes from the same patients produced lower amount of IL-2 than controls. These findings could not be explained by concurrent therapy. The increase of IL-1 production was more marked in patients with active disease and therefore may have been secondary to the pathological process. However, the decrease of IL-2 production did not depend on disease activity, thus suggesting an immunoregulatory abnormality.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3090248

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

1.  Immunoregulatory lymphokines in rheumatoid joints. II. Production by and responsiveness to interleukin-2 of eluted synovial tissue cells.

Authors:  J Hovdenes; T Egeland
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

2.  Synovial fluid cells in juvenile arthritis: evidence of selective T cell migration to inflamed tissue.

Authors:  E D Silverman; B Isacovics; D Petsche; R M Laxer
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

3.  Monocytes are resistant to apoptosis in systemic juvenile idiopathic arthritis.

Authors:  Shivani Srivastava; Claudia Macaubas; Chetan Deshpande; Heather C Alexander; Sheng-Yung Chang; Yue Sun; Jane L Park; Tzielan Lee; Ann Begovich; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2010-05-11       Impact factor: 3.969

4.  Decreased fibrinolytic activity in juvenile chronic arthritis.

Authors:  L Mussoni; G Pintucci; G Romano; F De Benedetti; M Massa; A Martini
Journal:  Ann Rheum Dis       Date:  1990-12       Impact factor: 19.103

Review 5.  Biologics in children's autoimmune disorders: efficacy and safety.

Authors:  Luciana Breda; Marianna Del Torto; Sara De Sanctis; Francesco Chiarelli
Journal:  Eur J Pediatr       Date:  2010-06-17       Impact factor: 3.183

Review 6.  Use of biologics in the treatment of childhood rheumatic diseases.

Authors:  T Arkachaisri; T J Lehman
Journal:  Curr Rheumatol Rep       Date:  2000-08       Impact factor: 4.592

7.  Prevalence of anticardiolipin antibodies in juvenile chronic arthritis.

Authors:  R Caporali; A Ravelli; F De Gennaro; G Neirotti; C Montecucco; A Martini
Journal:  Ann Rheum Dis       Date:  1991-09       Impact factor: 19.103

Review 8.  Autoantibody profile in juvenile chronic arthritis.

Authors:  A M Leak
Journal:  Ann Rheum Dis       Date:  1988-03       Impact factor: 19.103

9.  Lymphokines and soluble interleukin-2 receptors in juvenile chronic arthritis. Clinical and laboratory correlations.

Authors:  K Müller; F K Pedersen; A Wiik; K Bendtzen
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

10.  Alterations of in vitro interleukin 1 and 2 in diabetic children.

Authors:  R Lorini; D Montagna; A Lanfranchi; L Cortona; C Livieri; D Larizza; G d'Annunzio; F Severi
Journal:  Eur J Pediatr       Date:  1989-08       Impact factor: 3.183

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.